Pipeline
The Science
About us
Investors
News

Hit enter to search or ESC to close

Link to XBRL Interactive Data 30 June 2018

September 3, 2018 Kerry Rowe

https://www.sec.gov/cgi-bin/viewer?action=view&cik=1131343&accession_number=0001144204-18-047425&xbrl_type=v

Post navigation

PBT434 data to be presented at the International Congress of Parkinson’s Disease and Movement Disorders

Pre-clinical evidence demonstrates PBT434 as a potential treatment for MSA

Related Posts

XBRL 30 June 2021 filed with the SEC

September 3, 2021September 3, 2021

Prana receives Orphan Designation for PBT434 for treatment of MSA

January 31, 2019

IMAGINE Phase 2 clinical trial Investor Conference call

March 1, 2014

Recent Posts

Presentation of New Biomarker Data at Scientific Congress
XBRL 30 June 2021 filed with the SEC
Alterity Announces New US Patent to Expand its Portfolio of Compounds for Neurodegenerative Diseases including Alzheimer’s and Parkinson’s
Quarterly Cash Flow Report
New Publication Demonstrates ATH434 is Neuroprotective

Recent Comments

Archives

Archives

Categories

ASX Announcements
Investor Announcement

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065